Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 3, 2011, Pages 133-145

  St Jacques, René ^a   Toulmond, Sylvie ^a   Auger, Anick ^a   Binkert, Christoph ^b   Cromlish, Wanda ^a   Fischli, Walter ^b   Harris, Jennifer ^a   Hess, Patrick ^b   Jie Lan, ^a   Liu, Susana ^a   Riendeau, Denis ^a   Steiner, Beat ^b   Percival, M David ^c  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c Xenon Pharmaceuticals Inc   (Canada)

Author keywords

angiotensinogen; double transgenic; enalapril; expression; mRNA; Renin; rhesus

Indexed keywords

ALISKIREN; ANGIOTENSINOGEN; ENALAPRIL; LOSARTAN; MESSENGER RNA; RENIN; RENIN INHIBITOR;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DOSAGE; HYPERTENSION; KIDNEY; MEAN ARTERIAL PRESSURE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHESUS MONKEY; SPRAGUE DAWLEY RAT; TELEMETRY; TISSUE DISTRIBUTION; TREATMENT DURATION;

AMIDES; ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENALAPRIL; FEMALE; FUMARATES; GENE EXPRESSION REGULATION; HEART RATE; HUMANS; HYPERTENSION; MACACA MULATTA; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RENIN; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 80052388007     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310392618     Document Type: Article

References (29)

1. Bohlender J., Fukamizu A., Lippoldt A., Nomura T., Dietz R., Menard J., et al. High human renin hypertension in transgenic rats. Hypertension 1997 ; 29: 428-434. (Pubitemid 27074079)
2. Luft FC, Mervaala E., Muller DN, Gross V., Schmidt F., Park JK, et al. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension 1999 ; 33: 212-218. (Pubitemid 29065662)
3. Mervaala E., Muller DN, Schmidt F., Park JK, Gross V., Bader M., et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000 ; 35: 587-594. (Pubitemid 30108153)
4. Mervaala EM, Muller DN, Park JK, Schmidt F., Lohn M., Breu V., et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999 ; 33: 389-395. (Pubitemid 29065690)
5. Shagdarsuren E., Wellner M., Braesen JH, Park JK, Fiebeler A., Henke N., et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005 ; 97: 716-724. (Pubitemid 41416341)
6. Wellner M., Dechend R., Park JK, Shagdarsuren E., Al Saadi N., Kirsch T., et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics 2005 ; 20: 256-267. (Pubitemid 40388525)
7. Fischer R., Dechend R., Qadri F., Markovic M., Feldt S., Herse F., et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008 ; 51: 540-546. (Pubitemid 351156445)
8. Marki HP, Binggeli A., Bittner B., Bohner-Lang V., Breu V., Bur D., et al. Piperidine renin inhibitors: from leads to drug candidates. Farmaco 2001 ; 56: 21-27. (Pubitemid 32372577)
9. Dechend R., Shagdarsuren E., Gratze P., Fiebeler A., Pilz B., Meiners S., et al. Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst 2007 ; 8: 81-84. (Pubitemid 47272471)
10. Pilz B., Shagdarsuren E., Wellner M., Fiebeler A., Dechend R., Gratze P., et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005 ; 46: 569-576. (Pubitemid 41376839)
11. Thatcher S., Yiannikouris F., Gupte M. and Cassis I. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 2009 ; 302: 111-117.
12. Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010 ; 50: 439-465.
13. Fischli W., Clozel JP, el Amrani K., Wostl W., Neidhart W., Stadler H., et al. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension 1991 ; 18: 22-31.
14. Cauchon E., Liu S., Percival MD, Rowland SE, Xu D., Binkert C., et al. Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology. Anal Biochem 2009 ; 388: 134-139.
15. Bateman KP, Castonguay G., Xu L., Rowland S., Nicoll-Griffith DA, Kelly N., et al. Reduction of animal usage by serial bleeding of mice for pharmacokinetic studies: application of robotic sample preparation and fast liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2001 ; 754: 245-251. (Pubitemid 32241089)
16. Burnham CE, Hawelu-Johnson CL, Frank BM and Lynch KR Molecular cloning of rat renin cDNA and its gene. Proc Natl Acad Sci USA 1987 ; 84: 5605-5609.
17. Wood JM, Maibaum J., Rahuel J., Grutter MG, Cohen NC, Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 ; 308: 698-705. (Pubitemid 36976519)
18. Mervaala E., Dehmel B., Gross V., Lippoldt A., Bohlender J., Milia AF, et al. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol 1999 ; 10: 1669-1680. (Pubitemid 29364665)
19. Ganten D., Wagner J., Zeh K., Bader M., Michel JB, Paul M., et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992 ; 89: 7806-7810.
20. Feldman DL, Jin L., Xuan H., Contrepas A., Zhou Y., Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008 ; 52: 130-136.
21. Dehmel B., Mervaala E., Lippoldt A., Gross V., Bohlender J., Ganten D., et al. Pressure-natriuresis and -diuresis in transgenic rats harboring both human renin and human angiotensinogen genes. J Am Soc Nephrol 1998 ; 9: 2212-2222. (Pubitemid 28543799)
22. Weisinger RS, Begg DP and Jois M. Antagonists of the renin-angiotensin system and the prevention of obesity. Curr Opin Investig Drugs 2009 ; 10: 1069-1077.
23. Stucchi P., Cano V., Ruiz-Gayo M. and Fernandez-Alfonso MS Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009 ; 158: pp. 771-778.
24. Gratze P., Boschmann M., Dechend R., Qadri F., Malchow J., Graeske S., et al. Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 2009 ; 53: 516-523.
25. Wood JM, Schnell CR, Cumin F., Menard J. and Webb R. l. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005 ; 23: 417-426. (Pubitemid 40279646)
26. Sealey JE and Laragh JH Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007 ; 20: 587-597. (Pubitemid 46678721)
27. Krop M., Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008 ; 52: 1076-1083.
28. Krop M. and Danser AH Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr Hypertens Rep 2008 ; 10: 112-118.
29. Crowley SD and Coffman TM In hypertension, the kidney breaks your heart. Curr Cardiol Rep 2008 ; 10: 470-476.